Rep. Gilbert Ray Cisneros, Jr. Sells Insmed, Inc. (NASDAQ:INSM) Shares

Posted by Defense World Staff on Oct 15th, 2025

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Insmed, Inc. (NASDAQ:INSM). In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insmed stock on September 22nd.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 10/1/2025.
Sold $1,001 – $15,000 in shares of Amdocs (NASDAQ:DOX) on 10/1/2025.
Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 9/30/2025.
Sold $15,001 – $50,000 in shares of Fortive (NYSE:FTV) on 9/30/2025.
Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 9/30/2025.
Purchased $1,001 – $15,000 in shares of APi Group (NYSE:APG) on 9/30/2025.
Sold $1,001 – $15,000 in shares of GoDaddy (NYSE:GDDY) on 9/30/2025.
Purchased $1,001 – $15,000 in shares of PTC (NASDAQ:PTC) on 9/30/2025.
Purchased $1,001 – $15,000 in shares of CoStar Group (NASDAQ:CSGP) on 9/30/2025.
Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 9/30/2025.

Insmed Price Performance

Shares of NASDAQ INSM opened at $161.38 on Wednesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The stock has a fifty day moving average price of $140.13 and a 200 day moving average price of $103.17. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $166.44. The company has a market cap of $34.11 billion, a PE ratio of -28.26 and a beta of 1.03.

Insmed (NASDAQ:INSM – Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. During the same period in the prior year, the business earned ($1.94) earnings per share. Insmed’s revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC increased its position in shares of Insmed by 10.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 307 shares in the last quarter. NBC Securities Inc. purchased a new position in shares of Insmed in the first quarter valued at $49,000. Park Avenue Securities LLC increased its position in shares of Insmed by 38.7% in the first quarter. Park Avenue Securities LLC now owns 11,036 shares of the biopharmaceutical company’s stock valued at $842,000 after buying an additional 3,081 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Insmed by 62.0% in the first quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 386 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its position in shares of Insmed by 8.6% in the first quarter. Handelsbanken Fonder AB now owns 49,181 shares of the biopharmaceutical company’s stock valued at $3,752,000 after buying an additional 3,900 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a report on Wednesday, October 8th. Morgan Stanley increased their price target on Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Evercore ISI reaffirmed an “outperform” rating and set a $180.00 price target on shares of Insmed in a report on Wednesday, October 1st. Mizuho increased their price objective on Insmed from $130.00 to $165.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 13th. Finally, William Blair initiated coverage on Insmed in a research report on Wednesday, August 20th. They issued an “outperform” rating for the company. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $152.88.

Get Our Latest Analysis on Insmed

Insiders Place Their Bets

In other news, insider Michael Alexander Smith sold 24,272 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total value of $3,492,498.08. Following the completion of the transaction, the insider owned 54,902 shares in the company, valued at $7,899,848.78. This trade represents a 30.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of the firm’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the transaction, the director owned 262,675 shares of the company’s stock, valued at approximately $38,190,318.25. This represents a 3.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 211,057 shares of company stock valued at $27,438,126. Company insiders own 3.00% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.